Navigation Links
BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
Date:1/19/2012

FREDERICK, Md., Jan. 19, 2012 /PRNewswire/ -- BioElectronics Corporation. (OTC-PINK: BIEL), the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced the acceptance for publication of an article in the peer reviewed journal The Journal of Foot and Ankle Surgery. The article documents the clinical trial results of BioElectronics' study of its medical device on plantar fasciitis.

Plantar fasciitis, or heel pain, is a very common complaint which affects up to two million people in the United States yearly, in a multi-million dollar treatment market. Plantar fasciitis heel pain, with the current treatment options, can persist up to one or two years and can be extremely painful and debilitating. 

"With this published clinical trial, which was a placebo controlled, randomized and double blind study, BioElectronics is demonstrating that its patented pulsed radiofrequency electromagnetic field therapy medical device offers a rapid and economical resolution of the heel pain, and consequently is a significant advancement over current treatment options," said Ian Rawe, PhD, BioElectronics Director of Clinical Research. "The publication of these results will help introduce to the medical community a drug-free treatment featuring our unique medical device as an orthopedic pain therapy. We anticipate strong interest which will lead to expanded clinical study on a variety of orthopedic conditions." 

BioElectronics is currently conducting a second clinical study on plantar fasciitis using its revolutionary 'Smart Insole,' which provides a simple, 24-hour treatment option. With this new study, BioElectronics anticipates that it is moving toward making its therapy the treatment of choice in people suffering from plantar fasciitis.

About BioElectronics Corporation

BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:
Paul Knopick
E & E Communications
(949) 707-5365
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
2. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
5. BioElectronics Announces Major Clinical Trials
6. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
7. Incisive Surgical Announces Breakthrough Peer Review Clinical Study
8. Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies
9. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
11. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins ... athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in ... in water-related accidents and drownings during the summer. While most of us assume this ... situations occur every day. Very few people are taking the time to learn how ...
Breaking Medicine News(10 mins):